Avant Diagnostics (OTCMKTS:AVDX) and Fly Leasing (NYSE:FLY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.
Volatility and Risk
Avant Diagnostics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Fly Leasing has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
This table compares Avant Diagnostics and Fly Leasing’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avant Diagnostics||$110,000.00||33.70||-$11.75 million||N/A||N/A|
|Fly Leasing||$353.25 million||0.99||$2.59 million||$0.09||135.11|
Fly Leasing has higher revenue and earnings than Avant Diagnostics.
Insider and Institutional Ownership
0.0% of Avant Diagnostics shares are owned by institutional investors. Comparatively, 49.5% of Fly Leasing shares are owned by institutional investors. 38.0% of Avant Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Avant Diagnostics and Fly Leasing, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fly Leasing has a consensus price target of $19.83, suggesting a potential upside of 63.10%. Given Fly Leasing’s higher probable upside, analysts plainly believe Fly Leasing is more favorable than Avant Diagnostics.
This table compares Avant Diagnostics and Fly Leasing’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Fly Leasing beats Avant Diagnostics on 8 of the 11 factors compared between the two stocks.
Avant Diagnostics Company Profile
Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer; and MSPrecise, a DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company is based in Washington, District of Columbia.
Fly Leasing Company Profile
Fly Leasing Limited, through its subsidiaries, purchases and leases commercial aircrafts under multi-year contracts to various airlines worldwide. As of December 31, 2017, the company had a portfolio of 85 aircrafts, including 73 narrow-body passenger aircrafts and 12 wide-body passenger aircrafts. Fly Leasing Limited was founded in 2007 and is headquartered in Dún Laoghaire, Ireland.
Receive News & Ratings for Avant Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avant Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.